MedTrace Logo

Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence

NCT00603343 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 303

Last updated 2008-01-29

No results posted yet for this study

Summary

The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.

Conditions

Interventions

DRUG

Mictonetten 5 mg, coated tablet

propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)

DRUG

placebo

placebo corresponding to body weight

Sponsors & Collaborators

  • APOGEPHA Arzneimittel GmbH

    lead INDUSTRY

Principal Investigators

  • Daniela Marschall-Kehrel, MD · urologist

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2006-09-30
Completion
2006-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603343 on ClinicalTrials.gov